PhaBuilder announced that it has received $53.4 million in funding from Sino Biological,Inc., Beijing Zhonghai Investment Management Co., Ltd., Shanghai Free Trade Zone Equity Fund Management Co., Ltd., Chengtong Fund Management Co., Ltd., CNPC Kunlun Capital Co., Ltd., Shanghai Lingang Innovation Center Co., Ltd.
February 01, 2023
Share
PhaBuilder announced that it has raised $53.4 million in a round of funding led by CNPC Kunlun Capital Co., Ltd. on February 2, 2023. The transaction included participation from Sino Biological,Inc., Beijing Zhonghai Investment Management Co., Ltd., China State-owned Enterprise Mixed Ownership Reform Fund Co., Ltd., a fund managed by Chengtong Fund Management Co., Ltd., Shanghai Lingang Innovation Center Co., Ltd., Shanghai Free Trade Zone Equity Fund, a fund managed by Shanghai Free Trade Zone Equity Fund Management Co., Ltd.
Sino Biological Inc is a China-based biotechnology company engaged in the research and development, production, sales and technical services of biological reagents. The Company's main business includes products such as recombinant proteins, antibodies, genes and culture media, as well as the development of recombinant proteins and antibodies, and biological analysis and testing services. The Company operates in the domestic market and overseas markets.
PhaBuilder announced that it has received $53.4 million in funding from Sino Biological,Inc., Beijing Zhonghai Investment Management Co., Ltd., Shanghai Free Trade Zone Equity Fund Management Co., Ltd., Chengtong Fund Management Co., Ltd., CNPC Kunlun Capital Co., Ltd., Shanghai Lingang Innovation Center Co., Ltd.
SINO BIOLOGICAL,INC. 
